. Excellent reviews have been written on the current understanding of electro-mechanical coupling mechanisms during the gating process [5] [6] [7] . All 40 K V channels encoded by the human genome have been cloned and their biophysical properties characterized in minute detail. However, it often remains a challenge to determine precisely which channel underlies a K + current in a native tissue. This is because, within subfamilies, such as the K V 1 or K V 7 families, the α-subunits can heteromultimerize relatively freely, resulting in a wide range of possible channel tetramers with different biophysical and pharmacological properties 8 . The properties of K V channel α-subunit complexes can be further modified by association with intracellular β-subunits. For example, K V 1 family channels interact through their amino-terminal tetramerization domain with K V β1-3 proteins, which form a second symmetrical tetramer on the intracellular surface of the channel (see the figure in BOX 1) and modify the gating of the α-subunits. K V channel-interacting proteins 1-4 enhance the surface expression and alter the function of K V 4 channel α-subunits 8 . In addition to this 'mixing and matching' of α-and β-subunits, K V channel properties can be further modified by phosphorylation, dephosphorylation, ubiquitylation, sumoylation and palmitoylation. In terms of drug discovery, this molecular diversity creates a challenge. However, it also provides an opportunity to achieve selectivity by designing modulators that discriminate between homotetramers and heteromultimers or that bind to tissue-specific β-subunits 9 .
Because of the concentration gradient for K + that exists across the cell surface membrane, the opening of K V channels results in an efflux of positive charge, which can serve to repolarize or even hyperpolarize the membrane. In excitable cells such as neurons or cardiac myocytes, K V channels are therefore often expressed together with voltage-gated Na + and/or voltage-gated Ca 2+ (Ca V ) Nature Reviews | Drug Discovery
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channels and are responsible for repolarization after action potential firing. Pharmacological activation of K + channels in excitable cells consequently reduces excitability, whereas channel inhibition has the opposite effect and increases excitability (FIG. 1) . In both excitable and non-excitable cells, K V channels also play an important part in Ca 2+ signalling, volume regulation, secretion, proliferation and migration. In proliferating cells, such as lymphocytes or cancer cells, K V channels provide the counterbalancing K + efflux for the Ca 2+ influx through store-operated inward-rectifier Ca 2+ channels -such as the Ca 2+ release-activated Ca 2+ channel (CRAC) 10, 11 or transient receptor potential (TRP) channels -which is necessary for cellular activation. In this case, K V channel blockers inhibit proliferation and suppress cellular activation 10, 12 . It is well established that both migration and metastases require Ca 2+ influx through CRAC 13 or TRP subfamily V member 2 (ReF. 14) . In this context, K + channels have been traditionally viewed as modulators of the driving force for Ca 2+ influx. However, although no K V channels have been found to have intrinsic catalytic functions (in the sense of the protein kinase activity of TRP subfamily m (TRPm) channels), they often form part of large supramolecular complexes. The behaviour of these complexes can be influenced by the channel in the absence of ion flow. Therefore, non-canonical (nonconductive) properties of K V channels are increasingly found to be of importance [15] [16] [17] [18] . K V channels can also play a key part in preventing depolarization following activation of electrogenic transporters, including Na + -coupled glucose and amino-acid transporters in cells such as proximal tubule endothelial cells, which have to sustain large fluxes of cations or anions 19 . overall, K V channels therefore constitute potential drug targets for the treatment of diverse disease processes ranging from cancer to autoimmune diseases to metabolic, neurological and cardiovascular disorders. However, K V channels -in particular K v 11.1 (also known as HERG and KCNH2) with its promiscuous blocker-binding pocket and its relevance for cardiac repolarization -also present a challenge to drug discovery, owing to drug-induced arrhythmias. The therapeutic potential of K V channel modulation is further underscored by the phenotypes of transgenic mice and is associated with various human 'channelopathies' that are caused by mutations in K V channel genes (discussed below and in TABLe 1) . This article considers pharmacological strategies for targeting K V channels with venom peptides, antibodies and small molecules, and reviews recent progress in the preclinical and clinical development of drugs that target the K V 1 subfamily, the K V 7 subfamily (also known as KCNQ), K V 10.1 (also known as EAG1 and KCNH1) and K V 11.1 channels. Channels for which there is currently no pharmacological data will not be discussed in detail but are listed in TABLe 1 together with their potential therapeutic importance.
Pharmacological channel modulation strategies
Agents that modulate K V channels can be broadly divided into three chemical categories: metal ions, organic small molecules (molecular weight 200-500 da) and venom peptides (molecular weight 3-6 kda) 9 . These substances affect K V channel function by blocking the ion-conducting pore from the external or internal side, or modifying channel gating through binding to the voltage sensor domain or auxiliary subunits
. Similar to other proteins expressed on the cell surface, K V channels can be targeted with antibodies (molecular weight 150 kda), which can inhibit channel function, lead to channel internalization or deplete channel-expressing cells by complement-or cell-mediated cytotoxicity. Antibodies and toxins can also be engineered to serve as carriers for the delivery of active compounds to channel-expressing cells, or can be conjugated to cytotoxic drugs, isotopes
Box 1 | Interactions of venom peptides and small molecules with K V channels
The figure illustrates the structure of the voltage-gated K + channel 1.2 (K V 1.2; also known as KCNA2) (ReF. 3) with the S5-P-S6 region coloured green, the voltage sensor domain (S1-S4) coloured light grey, the tetramerization (T1) domain coloured orange and the intracellular K V β2 subunit coloured magenta. For clarity, only two of the four subunits are shown.
Peptide toxins (see ReF. 234 for a systematic nomenclature) typically contain 18-60 amino-acid residues and are cross-linked by 2-4 disulphide bridges, forming compact molecules that are remarkably resistant to denaturation. Peptide toxins can affect K V channels by two mechanisms: toxins from scorpions, sea anemones, snakes and cone snails bind to the outer vestibule of K + channels and in most cases insert a lysine side chain into the channel pore, occluding it like a cork in a bottle [235] [236] [237] . By contrast, spider toxins, such as hanatoxin, interact with the voltage sensor domain of K V channels and increase the stability of the closed state 238, 239 . The resulting rightward shift in activation voltage and acceleration of deactivation means that the channel is more difficult to open (that is, it requires more membrane depolarization) and closes faster. These 'gating-modifier' toxins typically contain a cluster of hydrophobic residues on one face of the molecule and seem to partition into the membrane when they bind to the voltage sensor 240, 241 . In contrast to peptide toxins, which affect K V channels from the extracellular side, most small molecules bind to the inner pore, the gating hinges or the interface between the α-and β-subunit. or other molecules. In terms of channel inhibition, one study has reported the development of monoclonal antibodies (specific for K V 10.1), although polyclonal antibodies have been obtained in several cases using extracellular parts of the pore loop as antigen 20 . Peptide toxins typically bind either to the outer vestibule or the voltage sensor of K V channels. By contrast, small molecules -as exemplified by the hydrophobic cations tetrabutylammonium (compound 1) (FIG. 2) , d-tubocurarine (compound 2) and verapamil (compound 3) -block K V channels by physically occluding the inner pore and inserting their ammonium group into the ion permeation pathway
. The inner pore of K V channels can also be targeted by nucleophilic molecules such as the K V 1 channel blocker correolide (compound 11), which fits neatly into the hydrophobic surface of the S6 helix with its lipophilic domain and chelates a permeating K + with its polar acetyl groups 21 . Typical blockers of K V 11.1 enter the channel from the intracellular side and seem to reside in a pocket in the inner mouth, where they interact mostly with two aromatic residues 22 . The wide range of drugs that this pocket can accommodate might be due to the lack of a cluster of proline residues, which induces a kink in the intracellular channel pore opening of K V channels, in contrast to other K + channel families 23 . This produces a broader opening in K V 11.1 that allows entry of a wide range of molecules of varying sizes and shapes 24 . In addition to the inner pore, small molecules can also bind to the 'gating hinges' . This occurs in the case of the K V 7 channel activator retigabine, which has been found by mutagenesis to bind to a putative hydrophobic pocket that is formed following channel opening between the cytoplasmic parts of S5 and S6 (ReF. 25) .
Another interesting mechanism of action for channels with β-subunits are the so-called disinactivators that disrupt the interaction between α-and β-subunits and thereby modify channel behaviour 26, 27 . However, rational design of K V channel modulators is extremely difficult because no crystal structures have yet been solved for medically important K V channels, such as K V 1.5 (also known as KCNA5), K V 7.2 (also known as KCNQ2) or K V 11.1. only two crystal structures in the K V channel field have been resolved -the bacterial K V AP and the mammalian K V 1.2 (also known as KCNA2) channels (both in the open state) -and no structure of a channel with a drug molecule bound has been resolved. K V channel modulators are therefore typically identified through high-throughput screening (BOX 2) or serendipity and then optimized through classical medicinal chemistry. lead identification is usually achieved by ion flux assays (mostly using isotopes and/or atomic absorption spectroscopy) or fluorescent dye assays 28 . more recently, it has been achieved through automated electrophysiology, which can offer quality levels comparable to that of manual patch clamp assays and has a reasonable throughput. detailed studies on functional drug-target interactions can be achieved through patch clamping, which allows the behaviour of a single ion channel to be studied on the microsecond timescale. Transmission of information in the nervous system is encoded in the frequency of electrical action potential firing in nerve fibres. Pathological changes in action potential firing frequency can lead to various neurological and psychological disorders. As voltage-gated K + channels (K V ) play important parts in defining the action potential waveform, modulators of these channels are expected to have therapeutic utility in such disorders. For example, under conditions in which action potential firing is decreased (specifically, in depression and cognitive dysfunction) K V channel blockers should restore normal firing. By contrast, K V channel activators should be useful to reduce pathological hyperexcitability (specifically, in epilepsy and pain) by reducing action potential firing. ADHD, attention deficithyperactivity disorder; CNS, central nervous system. K V 5, K V 6, K V 8 and K V 9 channels are not functional alone; they coassemble with K V 2 subunits and modify their function. § K V 11.2 is expressed in the CNS and on endocrine cells; K V 11.3 and K V 12.1-K V 12.3 are expresssed in the CNS; no data are reported on these channels regarding channelopathies, transgenic mice and therapeutic importance. ADHD, attention deficit-hyperactivity disorder; BFNC, benign familial neonatal convulsions; CCR7, CC-chemokine receptor 7; CNS, central nervous system; GABA, γ-aminobutyric acid; I Kur , ultra rapid delayed rectifier K + current; I to , transient outward K + current; I to,f , fast transient outward K + current; LPS, lipopolysaccharide; LQTS, long QT syndrome; MS, multiple sclerosis; NREM, non-rapid eye movement; PTZ, pentylenetetrazole.
K V 1 family channels Channels belonging to the K V 1 or mammalian Shakerfamily are widely expressed throughout the nervous system. of the eight known pore-forming subunits of this family (K V 1.1 (also known as KCNA1)-K V 1.8 (also known as KCNA10)), most have been shown to form heteromultimers in the central nervous system (CNS). The exact composition of neuronal K V 1 channels remains to be fully elucidated. However, in general, most forms of neuronal K V 1 channels are thought to contain at least one K V 1.1 and/or K V 1.2 subunit 29 , and these two channels are therefore regarded as targets for various CNS disorders. K V 1 family channels are also found in peripheral tissues such as the heart, the vasculature and the immune system. In these tissues, K V 1.5 and K V 1.3 (also known as KCNA3) are under investigation as targets for atrial fibrillation and immunosuppression, respectively. The therapeutic relevance of K V 1.4 (also known as KCNA4), K V 1.6 (also known as KCNA6), K V 1.7 (also known as KCNA7) and K V 1.8 is currently not clear.
The importance of K V 1.1 and K V 1.2 in controlling neuronal excitability has been shown by the ability of K V 1 channel-inhibiting venom toxins such as dendrotoxin to produce seizures in rodents 30 . Furthermore, K V 1.1-knockout mice exhibit spontaneous seizures and CNS structural changes 31 . Similarly, knockout of K V 1.2 in mice is associated with increased susceptibility to seizures 32 . In humans, several loss-of-function mutations in K V 1.1 have been linked to partial seizures, episodic ataxia and myokymia disorders 33 . moreover, lossof-function mutations in leucine-rich glioma-inactivated protein 1 (lGI1), which is co-expressed with K V 1.1, have been associated with temporal lobe epilepsy 34 . Normal lGI1 protein inhibits the K V β1 subunit-mediated inactivation of K V 1.1-K V 1.4 heteromultimeric channels, which increases the K + current and reduces neuronal excitability. By contrast, mutated lGI1 lacks the ability to abrogate K V β subunit-mediated inactivation 34 . Several small-molecule agents have been identified that are functionally equivalent to lGI1 and reverse or prevent K V β1 subunit-mediated inactivation of K V 1.1. Various techniques including a yeast two hybrid-based screen have been used to identify disinactivators of protein-protein interactions between β-subunits and pore-forming α-subunits 26, 27 . Several structural classes of compounds (see FIG. 2 for examples) have been reported to interact directly with the K V β1 N-terminus or its receptor site on K V 1.1, preventing inactivation of the channel. In addition to increasing current flow, these K V 1.1 disinactivators effectively reduce pentylenetetrazole (PTZ)-induced and maximal electric-shock-induced seizures in mice 27 . Accordingly, compounds that act by this mechanism have the potential to reduce neuronal hyperexcitability in epilepsy and pain disorders. However, the current development status of this therapeutic strategy is unknown. using a different screening strategy termed leptics technology 35 , investigators have recently identified both activators and inhibitors of K V 1.1 function that modulate β-subunit protein-protein interactions with K V 1 pore-forming α-subunits 36 .
Whereas activation of K V 1.1 and K V 1.2 channels is expected to reduce neuroexcitability (FIG. 2) , there are physiological and pathophysiological situations in which electrical signalling in the nervous system is reduced and needs to be amplified. damage to nerves caused by trauma (specifically, spinal cord injury) or disease (specifically, multiple sclerosis) is often associated with a decreased ability to generate and propagate action potentials 37, 38 . Neuronal damage is typically manifested as a loss of myelin, resulting in the uncovering of juxtaparanodal K V 1.1 and K V 1.2 channels and their redistribution along damaged axons 37, 39 . The presence of newly exposed K V channels slows and sometimes prevents conduction of electrical signals along the axon. Studies have shown that inhibition of these axonal K V 1.1 and K V 1.2 channels by the non-selective K + channel inhibitor 4-aminopyridine (4-AP) (compound 4) improves impulse conduction in damaged nerve fibres. This resulted in speculation that 4-AP might provide a treatment opportunity for spinal cord injury 37 . Indeed, Phase II clinical trial data for a slow-release formulation of 4-AP, fampridine SR, to treat spinal cord injury were encouraging. However, in two subsequent larger Phase III clinical studies in patients with spinal cord injury, the drug failed to produce any statistically significant reduction in spasticity 38 . However, in a separate set of Phase III clinical studies, fampridine SR was found to improve walking ability in patients with multiple sclerosis 40, 41 . While these findings represent important progress in treating the symptoms of multiple sclerosis, the impact of fampridine SR on disease progression remains to be determined.
Although K V 1.1 is typically considered to be a neuronal channel, it has recently been linked to human autosomal dominant hypomagnesaemia 42 . A loss-offunction mutation in K V 1.1 reduces TRPm6-mediated mg 2+ reabsorption in the kidney -a function that depends on K V 1.1 setting a negative membrane potential 43 . Because of its fundamental role in many cellular functions, abnormalities in mg 2+ levels can result in widespread organ dysfunction, which can precipitate potentially fatal complications (for example, ventricular arrhythmia, coronary artery vasospasm and seizures). Pharmacological enhancement of available K V 1.1 channel activity might provide a therapeutic opportunity for treating hypomagnesaemia. (ReFs 10, 44, 45) . It was proposed as a target for immunosuppression because non-selective K + channel blockers such as 4-AP (compound 4) inhibit T cell proliferation and interleukin-2 secretion 44 . These findings were subsequently confirmed with the more K V 1.3-selective scorpion toxin margatoxin 46 , which was also found to suppress delayed-type hypersensitivity in miniature pigs, providing the first evidence that K V 1.3 blockade can inhibit immune responses in vivo 47 . K V 1.3 blockers exert their immunosuppressive effect by depolarizing the T cell membrane 46 and thus reducing the driving force for Ca 2+ entry through the CRAC channel 10 , which consists of the endoplasmic reticulum Ca As T cells are small and have no substantial intracellular Ca 2+ stores, this Ca 2+ influx through the inward rectifier CRAC is necessary for the translocation of nuclear factor of activated T cells to the nucleus and the ultimately resulting cytokine secretion and T cell proliferation. To be fully activated, the T cell must therefore retain a negative membrane potential by a counterbalancing K + efflux through K V 1.3 and/or the other T cell K + channel, K Ca 3.1. Small-molecule K V 1.3-targeted discovery programmes that were initiated in the mid-1990s failed to identify compounds that were sufficiently selective for in vivo use 51 . The Pfizer compounds CP-339818 (compound 9) (FIG. 2) and uK-78282 (compound 10) lacked selectivity over Na + channels or K V 1.4, and the molecular complexity of merck's nortriterpene correolide (compound 11) was too great for successful analogue development. Interest in K V 1.3 as a target for immunosuppression subsequently waned, partly because differences in T cell K + channel expression between mice and humans made it impossible to use the well-established mouse models of autoimmune diseases to evaluate K V 1.3 blockers. Interestingly, mice express additional K V channels, such as K V 1.1, K V 1.6 and K V 3.1 (also known as KCNC1), in their T cells 47, 52, 53 and do not rely on K V 1.3 to set their resting membrane potential. However, there has recently been a revival of interest in K V 1.3 as a drug target following the discovery that K V 1.3 blockers selectively inhibit the Ca 2+ signalling, proliferation and in vivo migration of CC-chemokine receptor 7 (CCR7) -effector memory T cells (T Em ) [54] [55] [56] . drugs that target K V 1.3 might therefore constitute immunomodulators rather than general immunosuppressants 57 . T Em are a memory T cell subset that is negative for CCR7 and has been implicated in the pathogenesis of T cell-mediated autoimmune diseases such as multiple sclerosis, type 1 diabetes, rheumatoid arthritis and psoriasis 55, [58] [59] [60] [61] . In keeping with this observation, myelin antigen-reactive T cells in the blood from patients with multiple sclerosis, islet antigen-reactive T cells from children with newonset type 1 diabetes, as well as synovial fluid T cells from patients with rheumatoid arthritis and brain-infiltrating T cells in postmortem brain sections from patients with multiple sclerosis, have all been shown to be K V 1.3 high CCR7
was discovered in human T cells in 1984
-T Em cells 54, 55, 61 . Similar to humans, rats, pigs and primates can upregulate K V 1.3 in their T Em cells, making it possible to evaluate the immunosuppressive effects of K V 1.3 blockers in these species.
The possibility that K V 1.3 could serve as a target for T Em -specific immunosuppression has led to the recent development of both peptidic and small-molecule K V 1.3 blockers. Sea anemone peptide K + channel toxin ShK effectively treats adoptive-transfer experimental autoimmune encephalomyelitis (EAE) in rats 62 . Subsequently, it was shown that ShK-l5 (ReF. 63 ), a ShK derivative with improved selectivity over K V 1.1, is therapeutically beneficial in pristane-induced arthritis and chronic relapsing EAE in rats 55, 56 . A close structural analogue of ShK-l5 is currently in preclinical development for multiple sclerosis, and attempts are being made to prolong the short half-life of venom peptides such as ShK or the scorpion peptide oSK1 by conjugating them to Fc antibody fragments 64 . Starting from two natural products, the psoralen 5-methoxypsoralen from the rue plant and the benzofuran khellinone from the toothpickweed, several classes of K V 1.3 inhibitors with affinities in the nanomolar to low micromolar range have been developed [65] [66] [67] . The most potent of these compounds, the psoralen PAP-1 (compound 12), inhibits K V 1.3 with a half-maximal inhibitory concentration (IC 50 ) of 2 nm. It has been shown to effectively treat rat allergic contact dermatitis 68 , which is a simple animal model of psoriasis, and to prevent spontaneous autoimmune diabetes in diabetes-prone Biobreeding Worcester rats 55 . The khellinone-type K V 1.3 blockers (exemplified by the chalcone (compound 13) and the 4-substituted khellinone (compound 14)) are currently being optimized for development for multiple sclerosis. Studies on clofazimine (compound 15) recently provided further evidence that K V 1.3 could be a target for immunosuppression in humans. Clofazimine is a drug that is marketed as lamprene by Novartis and has been clinically used since the 1960s for leprosy, pustular psoriasis, skin graft-versus-host disease and discoid lupus erythematosis. It inhibits K V 1.3 with an IC 50 of 400 nm and prevents the rejection of transplanted human foreskin in immunodeficient mice reconstituted with human T cells 69 . Clofazimine could therefore be used as a template for the design of K V 1. It is a high-fidelity but low-throughput platform that requires skilled operators. This technology is useful for investigating the biophysical properties and modulation of ion channels in general and K V channels in particular. However, it can only be used to examine a few compounds per day and is impractical in modern drug discovery, for which hundreds of thousands, and sometimes millions, of compounds need to be tested for activity.
To facilitate drug discovery programmes that target ion channels, a number of technologies have been developed. As with many drug target classes, radioligand-binding studies have proved successful in the identification of modulators of K V channels. Radioiodinated venom toxins such as margatoxin 243 or tritiated natural products such as correolide 244 have been used to identify modulators of K V 1.3 (also known as KCNA3) channels; radiolabelled dofetilide is regularly used to investigate potential modulators of K V 11.1 (also known as HERG and KCNH2) 245 . . Radioactive Rb + can also be replaced by unlabelled Rb + and then detected by atomic absorption spectroscopy 247 . More recently, thallium, to which K + channels are permeant, has been used successfully in high-throughput screening assays, in which it interacts with a preloaded intracellular fluorescent dye after passing through open K + channels 248 . Membrane potential-sensitive fluorescent dyes have also been used to examine compound interactions with K V channels 249 .
Perhaps the most important advancement in ion channel drug discovery in recent years has been the development of higher throughput electrophysiological platforms. These range from the medium-throughput systems -such as the high-fidelity PatchXpress (Molecular Devices) 250 , Qpatch (Sophion) 251, 252 or PatchLiner (Nanion) 253 , which can test up to 100 compounds per day -to higher-throughput platforms such as IonWorks HT and Quattro (Molecular Devices) 254, 255 and more recently Qpatch HTX (Sophion) that can test thousands of compounds per day. Although not truly high throughput, when used in conjunction with other screening technologies, these new electrophysiology platforms have allowed for a higher fidelity and more direct approach to K V channel drug discovery than was previously possible. More detailed discussions of screening for ion channel modulators can be found in several recent reviews 28, 256, 257 . enter clinical trials after careful consideration of its benefit versus its known risks, such as gastrointestinal intolerance and skin discolorations. Results obtained with clofazimine should be interpreted with caution as the compound has multiple activities on other targets and pathways, such as stimulation of phospholipases, increasing phagocytosis by macrophages or interactions with dNA. Based on experiments with K V 1.3 -/-mice, these channels have also been suggested as a target for the treatment of type 2 diabetes and obesity 70 . K V 1.3 -/-mice gained less weight on a high-fat diet than control mice and had increased insulin sensitivity owing to increased glucose uptake into adipose tissue and skeletal muscle. In these tissues in normal mice, blockade of K V 1.3 with margatoxin facilitates the translocation of glucose transporter type 4 to the plasma membrane and so improves insulin sensitivity 71 . Intriguingly, knockout of K V 1.3 can also reduce adiposity and increase lifespan in a genetic model of obesity. K V 1.3 and melanocortin receptor 4 (mC4R) doubleknockout mice had a lower bodyweight and an increased lifespan and reproductive success compared with mC4R -/-mice 72 . However, although it is certain that mouse adipocytes express K V 1.3 protein, electrophysiological studies on neonatal brown fat cells 73, 74 and white adipocytes from rats and adult humans 75, 76 show K V currents with different pharmacological and biophysical characteristics to that carried by K V 1.3 channel homotetramers. It is therefore unclear whether K V 1.3 could be a target for the improvement of insulin sensitivity and weight reduction in type 2 diabetes in humans. 
Delayed rectifier
A slowly activating and very slowly inactivating ion channel through which K + preferentially passes out of, rather than into, the cell.
Transient outward K + current
A rapidly activating and inactivating K + current.
Antiarrhythmic
An agent that decreases the incidence of arrhythmias. Class I agents interfere with the cardiac Na + current. Class II agents are anti-sympathetic nervous system agents (mostly beta blockers). Class III agents affect K + channels. Class IV agents affect voltage-gated Ca 2+ channels and the atrioventricular node. Class V agents work by other or unknown mechanisms.
K V 1.5. Although K V 1.5 is expressed in various tissues in humans [77] [78] [79] , its functional expression in atrial but not ventricular muscle in the heart 77 has made this channel the focus of considerable interest in the pharmaceutical industry. Studies in the early 1990s showed that K V 1.5 was the primary molecular component of the channel underlying the ultra rapid delayed rectifier current (I Kur ) 80, 81 . This human atrium-specific K + current plays an important part in the early phases of atrial action potential repolarization 82 (FIG. 3a) . This function, and its regiospecific localization, suggested K V 1.5 as an attractive target for the development of safer pharmacological interventions for atrial arrhythmias, particularly atrial fibrillation. The absence of functional K V 1.5 expression in the human ventricle reduces the risk of serious ventricular arrhythmias that can be induced by treatments targeting channels with broader expression in the heart 83, 84 . Given the ubiquitous expression of other K V 1 channels, efforts have been made to identify and develop K V 1.5-selective agents. development has been complicated by the fact that the importance of I Kur , or the contribution of K V 1.5 to I Kur -like currents, in atrial repolarization in the hearts of mice, rats, rabbits and dogs may be different from humans, making it difficult to evaluate antiarrhythmic efficacy in these species 84, 85 . despite these challenges, a number of pharmaceutical companies have attempted to develop K V 1.5 inhibitors for atrial fibrillation (FIG. 3b) . more than 50 patent applications for K V 1.5 inhibitors have been submitted (see ReF. 85 for a comprehensive review). one of the earliest attempts identified a number of potent K V 1.5 inhibitors, including arylsulphonamidoindanes 86 (compound 16) and subsequently tetrahydronapthalenes. However, these compounds were abandoned because of poor pharmacokinetic profiles. other compounds from these discovery programmes entered human clinical trials but did not progress beyond Phase I. other companies 83, [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] developing K V 1.5 inhibitors (compounds 17-22) have demonstrated varying degrees of atrium-specific modulation of action potential repolarization. However, the majority of these compounds have not progressed beyond animal efficacy testing, owing to pharmacodynamic or pharmacokinetic issues. However, the bisaryls AVE-0118 (compound 17) and AVE-1231 from Sanofi-Aventis 89, 90, 100, 101 , although at best weakly selective for K V 1.5, progressed into human testing, with AVE-0188 reaching Phase IIa trials before development ceased. Vernakalant (compound 18) is currently in the final stages of development after a completed Phase III study gained conditional approval from the uS Food and drug Administration (FdA) for intravenous conversion of atrial fibrillation to sinus rhythm. This compound has previously been shown to reduce atrial fibrillation in various animal models 97, 98 . Although it has been suggested that the primary target of vernakalant is K V 1.5, its mechanism of action probably involves blockade of several ion channels, including those responsible for the transient outward K + current (I to ) and the fast Na + current 97 (FIG. 3a) . A selective K V 1.5 inhibitor, XEN-d0101 (ReF. 85) , was effective in two preclinical canine models of atrial fibrillation 102, 103 and is currently undergoing Phase I evaluation as an intravenous treatment to terminate atrial fibrillation. K V 2.1 channels K V 2.1 encodes a classical delayed rectifier channel that is involved in neuronal repolarization. Its function can be diversified through heteromultimerization with the 'silent' K V 5, K V 6, K V 8 and K V 9 subunits (TABLe 1) , which modify inactivation, trafficking, drug sensitivity and expression of K V 2.1 (ReFs 104,105). K V 2.1 has recently been implicated in exocytic processes both in neurons and in pancreatic β-cells. In β-cells, inhibition of K V 2.1 enhances insulin secretion, suggesting a potential therapeutic strategy for type 2 diabetes 106, 107 . This effect apparently occurs, at least in part, through non-conducting functions -namely, a physical interaction with syntaxin (a component of the soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complex) that facilitates vesicle fusion 108, 109 . K V 3.4 channels of the Shaw-related family of mammalian K V channels, so far only K V 3.4 has been proposed as a drug target. K V 3.4 coassembles with K + voltage-gated channel subfamily E member 3 (KCNE3; also known as mIRP2) to give rise to I to in skeletal muscle and neurons 110 . In muscle, alterations in the function of the complex owing to mutations in the accessory subunit KCNE3 are associated with periodic paralysis 111 . Additionally, in nervous tissue, K V 3.4 has been related to neuronal death induced by β-amyloid peptides in Alzheimer's disease 112, 113 . K + depletion through hyperactivity of K V channels contributes to apoptotic neuronal death 114 , and blockade of K + channels has neuroprotective effects 115 . The expression of K V 3.4 is increased in the early stages of Alzheimer's disease and increases further as the disease advances 112 . In addition to these higher expression levels, the current carried by K V 3.4 is enhanced by β-amyloid peptide. The K V 3.4-blocking anemone toxin BdS simultaneously abolishes the increase in current and neuronal death 113 . Hence, blockade of K V 3.4 in the context of Alzheimer's disease could reduce neuronal loss and thereby cognitive impairment.
K V 4.2 and K V 4.3 channels
The Shal-type K V 4.2 and K V 4.3 channels are expressed at high levels in the brain and the heart, where they contribute to I to (FIG. 3a) . one remarkable feature of K V 4 channels is the complexity of their association with various ancillary subunits or scaffolding proteins and their extensive post-translational modification 116 . In terms of drug discovery, atrial and ventricular K V 4.3 channels could constitute targets for antiarrhythmic therapy. Indeed, inhibition of I to , which in humans is mediated by a K V 4.3 homotetramer 117 , seems to be one of the mechanisms of action of the class III antiarrhythmic agent tedisamil. However, in addition to I to, tedisamil also inhibits the rapid delayed rectifier K + current (I Kr ), the slow delayed rectifier K + current (I Ks ), I Kur and the ATP-dependent K + current (I K-ATP ) 118 . The FdA recently rejected an application for the use of tedisamil for the treatment of atrial arrhthymias. The future development of this compound remains unclear.
In addition to the potential utility of inhibitors, the important role of K V 4.2 in pain plasticity in dorsal 
QT interval
On an electrocardiogram, the QT interval represents the time between the electrical activation and the repolarization of the ventricles. It is measured from the onset of the Q wave to the end of the T wave.
horn neurons in the spinal cord 119 suggests that K V 4.2 activators might be useful for the treatment of inflammatory pain.
K V 7 family channels
The K V 7 family comprises five members: K V 7.1 (also known as KCNQ1), K V 7.2, K V 7.3 (also known as KCNQ3), K V 7.4 (also known as KCNQ4) and K V 7.5 (also known as KCNQ5). Whereas K V 7.1 is predominantly found in peripheral tissues, K V 7.2-K V 7.5 seem to be most widely expressed in the nervous system 120, 121 . K V 7.1. K V 7.1 is present in cardiac muscle, in which it is co-expressed with the auxiliary subunits KCNE1, KCNE2 and KCNE3 to form the functional channel responsible for I Ks 120, 122 . This current has an important role in controlling repolarization, and thus the duration, of the cardiac action potential (FIG. 4a) . In humans, numerous loss-of-function mutations in K V 7.1 or KCNE subunits (resulting in reduced current flow and prolongation of cardiac action potentials) have been identified in potentially life-threatening cardiac abnormalities -such as long QT syndrome (lQTS), in which the QT interval is prolonged 120, 123 . Several of these loss-offunction mutations in K V 7.1 are associated with Jervell and lange-Nielsen syndrome 124 , a condition with auditory abnormalities in addition to cardiac rhythm defects. Gain-of-function mutations in K V 7.1 increase current flow through the channel and lead to shortening of the cardiac action potential. They are associated with cardiac rhythm disorders such as short QT syndrome 125 and atrial fibrillation 126 . For more than a decade, the K V 7.2/KCNE-associated cardiac K + current has remained a target of interest for the development of antiarrhythmic drugs. Some marketed antiarrhythmic agents (for example, amiodarone) may produce their clinical effects in part through modulation of K V 7.1 or KCNE activity 127 . Azimilide (compound 23) (FIG. 4b) is a mixed inhibitor of K V 7.1 (which underlies I Ks ) and K V 11.1 (which underlies I Kr ) that has shown efficacy in various animal models of arrhythmia 128, 129 . 1; also known as KCNQ1) or K V 11.1 (also known as HERG and KCNH2) on action potential duration and length of QT interval. The current for which the channel is responsible is shown in brackets. Inhibition of K V 7.1 and K V 11.1 prolongs ventricular action potential duration. This is similar to acquired or hereditary long QT syndrome. Activators of K V 7.1 or K V 11.1 reduce the duration of cardiac action potential, which is manifested as a shorter QT interval. b | K V 7.1 inhibitors. Azimilide has been shown to reduce atrial fibrillation in clinical trials 128, 129 , and HMR-1556 (ReF. 134) However, when assessed in clinical trials, only limited efficacy in the conversion of atrial fibrillation to sinus rhythm was observed [130] [131] [132] . The current development status of azimilide is unknown. more selective inhibitors of K V 7.1, such as the chromanol HmR-1556 (compound 24) 133,134 and l-768673 (compound 25), have also been reported to prolong cardiac action potentials and reduce the incidence of arrhythmias in animal models. HmR-1556, which has greater than 1000-fold selectivity for I Ks over I Kr , restores sinus rhythm and prevents heart failure in pigs with persistent atrial fibrillation 135, 136 . In a canine model of vagal atrial fibrillation, HmR-1556 prolonged the atrial effective refractory period. However, it had only a modest effect on the duration of induced atrial fibrillation 137 . The acyl benzodiazepine l-768673 has been reported to increase ventricular refractoriness in conscious dogs 138 . despite the promising activities of these selective K V 7.1 inhibitors in animal models, neither seems to have been developed sufficiently to be assessed for clinical efficacy in humans.
In addition to inhibitors, several pharmacological activators of K V 7.1 (with or without KCNE1) channels have been reported. Niflumic acid (compound 26) and the structurally related mefenamic acid (compound 27) increase current flow through K V 7.1-KCNE1 by inducing hyperpolarizing shifts in the voltage dependence of activation 139 . The benzodiazepine l-364373 (compound 28) potently activates homomeric K V 7.1 channels but is considerably weaker when K V 7.1 is co-expressed with the auxiliary subunit KCNE1 (as occurs in the heart) 140, 141 . The therapeutic utility of K V 7.1 activators remains to be explored.
Although most well characterized in the heart, K V 7.1 is found in the inner ear and epithelial tissues of the kidney, lung and gastrointestinal tract 120 . In contrast to the heart, K V 7.1 channels in epithelial cells seem to be co-expressed primarily with KCNE3 to form a conductance that exhibits little time dependence with regard to activation and only weak sensitivity to membrane potential 142 . Gating of the channel is modulated through various second-messenger pathways, including cyclic AmP pathways 143, 144 . Epithelial K V 7.1 channels have an important role in maintaining the driving force for proximal tubular and intestinal Na + absorption, gastric acid secretion, and cAmP-induced jejunal Cl -secretion 120, 145 . Recent studies have also revealed an association of K V 7.1 with susceptibility to type 2 diabetes 146 . K V 7.1 activity seems to counteract the stimulation of cellular K + uptake into the liver by insulin and thereby influences K + -dependent insulin signalling 147 . The therapeutic utility of targeting K V 7.1 for diabetes or epithelial fluid transport disorders has yet to be explored. K V 7.2-K V 7.5. over the past decade, there has been considerable interest within the pharmaceutical industry to develop modulators of the neuronal K + conductance referred to as the M-current. It is so called because of its sensitivity to inhibitory modulation by various G protein-coupled receptor ligands, most notably muscarinic acetylcholine receptor agonists 148 . This current was first identified in the late 1970s and was subsequently shown to modulate synaptic plasticity and neuronal excitability in many areas of the brain 121, 148 . The molecular nature of the m-current only became evident following the characterization of loss-of-function mutations in a rare hereditary human epilepsy called benign familial neonatal convulsions 149 . At around the time of these studies, it was shown that K V 7.2 and K V 7.3, in heteromultimeric combination, were the molecular components of at least one form of the channel underlying the neuronal m-current 150 . Subsequent studies have indicated that heteromultimeric combinations of K V 7.3 and K V 7.5 may also underlie m-currents in some areas of the brain 151 . The contribution of K V 7.4 to the m-current is less clear. However, K V 7.4 is evidently important in auditory physiology, given its expression in hair cells of the cochlea. Furthermore, loss-of-function mutations or singlenucleotide polymorphisms in K V 7.4 are associated with autosomal dominant deafness 2A and age-related hearing impairment 152, 153 . Given the importance of K V 7.2-K V 7.5 in a wide range of neuronal processes, it is not surprising that considerable effort has been directed towards developing therapeutic agents that target these channels. more than 20 patents for new modulators of K V 7.2-K V 7.5 have been issued, and over 100 uS patent applications are currently at various stages of approval. Early studies with m-current inhibitors, such as linopirdine (compound 29) (FIG. 5) , demonstrated improvements in learning and memory performance in animals 154 . However, clinical trials did not provide conclusive results for the treatment of cognitive disorders 155 . Although secondgeneration inhibitors, such as XE-991 (compound 30) and dmP-543 (compound 31) were developed 156 , no further clinical efficacy studies investigating improvement of cognitive function have been reported.
In contrast to the abandoned inhibitors, there remains widespread interest in the pharmaceutical industry to develop m-current activators. The first agent that was proven to enhance m-current activity was retigabine (compound 32). Activation of recombinant K V 7.2/K V 7.3 by retigabine was confirmed independently by a number of investigators, who showed that current enhancement by retigabine resulted from a profound hyperpolarizing shift in the voltage dependence of channel activation [157] [158] [159] . When examined in vivo, retigabine exhibited anticonvulsant activity in a broad range of seizure models including PTZ-induced seizures, maximal electric shock, audiogenic seizures in dBA/2J mice as well as seizures produced by amygdala kindling 160 . Based on these findings, retigabine has been the subject of numerous clinical studies to assess its anticonvulsant activity in humans. Phase II 161, 162 and Phase III efficacy trials 163, 164 have been successfully completed. Retigabine is currently awaiting FdA approval as a new first-in-class epilepsy therapy.
A number of other K V 7.2-K V 7.5 activators have been identified including the benzanilide K V 7.2/K V 7.3 opener ICA-27243 (compound 34), which exhibits >30-fold selectivity for K V 7.2/K V 7.3 over K V 7.3/K V 7.5 hetero multi meric channels, or K V 7.1, K V 7.4 and K V 7.5 homomulti meric channels 165 . like retigabine, ICA-27243 shows efficacy in various animal seizure models 166 , providing evidence that selective activation of K V 7.2/ K V 7.3 is sufficient to achieve anticonvulsant activity. despite the promising in vivo activity of ICA-27243 (and a more advanced related compound, ICA-69673) in animal models, this class of agents has not been developed beyond Phase I clinical trials. However, a new, structurally distinct K V 7.2/K V 7.3 activator chemotype, exemplified by ICA-105665, is in development and is currently undergoing Phase II clinical trials 167 . The clear role of K V 7 channels in controlling neuronal excitability, combined with their expression in sensory and central neurons that are involved in nociceptive signalling 168, 169 , has further prompted the exploration of K V 7.2-K V 7.5 activators for the treatment of pain 170, 171 . Both retigabine and its structural analogue flupirtine (compound 33) produce analgesic activity in rat models of neuropathic pain [172] [173] [174] . Flupirtine has been in clinical use as an analgesic in Europe since 1984 and is currently in Phase II clinical trials in the united States for the treatment of fibromyalgia. However, a recently completed Phase IIa clinical trial of retigabine in patients with post-herpetic neuralgia failed to demonstrate significant antinociceptive activity. The K V 7.2/K V 7.3-selective activator ICA-27243 has shown significant oral antinocicep tive activity in animal models of inflammatory, chronic and neuropathic pain 175, 176 . Furthermore, numerous K V 7.2-K V 7.5 activator chemotypes (compounds 35 and 36) are reportedly effective in diabetic neuropathy and other rodent neuropathic pain models following intravenous administration 170, 177, 178 . A patent application has also been filed for the use of K V 7.2-K V 7.5 activators for the treatment of migraine pain 179 . Interestingly, diclofenac (compound 37), an 'old' non-steroidal antiinflammatory drug that is used clinically to treat inflammation and pain associated with arthritis, activates K V 7.2 channels, as do a number of related compounds (such as meclofenamic acid) 180 . Structural analogues of diclofenac such as NH6 (compound 38), which retain K V 7.2 channel-opening activity but lack cyclooxygenase-inhibiting activity, have recently been synthesized 181 and may allow assessment of the contribution of K V 7 channel opening to the analgesic activity of this class of agents.
Both selective and non-selective K V 7.2/K V 7.3 activators also exhibit efficacy in animal models of neuro psychiatric disorders such as anxiety, attention deficit-hyperactivity disorder, mania, bipolar disease and schizophrenia 182 . Retigabine and ICA-27243, but not the K V 7.4-K V 7.5-preferring activator BmS-204352, are effective in an amphetamine-and chlordiazepoxide-induced hyperactivity model of mania 183 . Similarly, retigabine has been shown to inhibit avoidance responses in a conditioned avoidance response model of antipsychotic activity. This effect was blocked by the K V 7 inhibitor XE-991 (ReF. 184 ). Furthermore, retigabine was able to inhibit hyper-locomotor responses in phencyclidine-sensitized animals, which is often used as a model of schizophrenia 184 . Similar effects are also produced by compound 39 (ReFs 185, 186) .
most of the interest in developing K V 7.2-K V 7.5 activators as therapeutic agents has focused on neurological or psychological disorders. However, the presence of these channels in the bladder and other urological tissues, together with the finding that K V 7.2-K V 7.5 activators can modulate bladder contraction and micturition responses in animal models, suggests that these agents might also be useful in the treatment of incontinence and related disorders 187 . K V 10.1 K V 10.1 gives rise to a slowly activating, non-inactivating K + current in heterologous systems. K V 10.1 mRNA 12, 188, 189 and protein 190 are abundant in the brain, but in peripheral tissues protein expression is restricted to particular cell populations 188 . Paradoxically, the only characterized physiological role of K V 10.1 is in skeletal muscle development, in which it is expressed during a limited time window when myoblasts exit the cell cycle and fuse 191 . deletion of exon 1 of the gene encoding K V 10.1 in mice results only in a mild increase in sensitivity to seizures (H. menke, dissertation, univ. Göttingen, 1998). most of the interest in K V 10.1 arises from its expression in up to 70% of tumour cell lines and human cancers. These include colon carcinoma 192, 193 (in which amplification of the gene has been detected by fluorescence in situ hybridization in 3.5% of cases and correlates with poor prognosis), gastric 194 and mammary tumours 188 and sarcomas 195 (in some of which channel expression also correlates with a poor outcome). Efforts to determine the mechanism underlying this expression pattern have been largely unsuccessful, although it has been reported that K V 10.1 expression is initiated after immortalization by papillomavirus oncogenes 196 . K V 10.1 expression might offer an advantage to tumours through increased vascularization and resistance to hypoxia 18 . However, this does not explain the observation that the proliferation of cell lines, derived from the tumour types mentioned above, is reduced by inhibiting the expression or function of K V 10.1 (ReF. 197) . Additionally, K V 10.1 expression seems to also affect cytoskeletal organization, which might influence proliferation and other properties of tumour cells, such as migration and metastasis 198 . Two potent blockers of K V 10.1, astemizole (compound 40) (FIG. 6) and imipramine (compound 41) have been shown to decrease tumour cell proliferation in vitro and, in the case of astemizole, also in vivo 195, [199] [200] [201] . In mouse models, oral doses of astemizole that are well below the toxic range reduced the progression of established subcutaneous tumours (melanoma and pancreatic and mammary carcinomas) and the frequency of metastasis in lung carcinoma models with a potency comparable to the maximal tolerable dose of the established chemotherapeutic agent cyclophosphamide 18 . Tests in humans will of course need to be conducted to clarify the predictive value of these observations. Additionally, both imipramine and astemizole block K V 11.1 and therefore pose cardiac risks (for example, see ReF. 202) ; it was for this reason that the antihistamine astemizole was withdrawn from the market in 2000. However, as discussed below for K V 11.1, the risk to benefit ratio for these drugs might need to be reconsidered for repositioning.
The intracellular channel pore openings of K V 10.1 and K V 11.1 are similar, although not identical 203 . Nevertheless, all known K V 10.1 blockers are also effective blockers of K V 11.1 and therefore share their cardiac safety problems. This has prompted the search for biological modulators that can differentiate between the two channel classes. A specific peptide toxin that can achieve this has yet to be reported. However, a monoclonal antibody (mAb56) has been developed that specifically blocks K V 10.1 without affecting K V 11.1 or the close relative K V 10.2 (ReF. 204) . The antibody showed efficacy in vitro against several tumour cell lines, and in vivo in certain tumour models, but the doses required were high and the reduction of tumour growth was modest. The experiments were performed in immunodeficient mice, so that the antibody could in principle act exclusively as a channel blocker. Interestingly, the role of K V 10.1 in tumour biology is not entirely mediated by K + permeation, as a non-conducting mutant preserves part of the pro-neoplastic properties of the wild-type channel 18 .
K V 11.1 K V 11.1 plays a crucial part in cardiac repolarization (FIG. 4a) , especially in the later phases of the action potential owing to its unique kinetics. upon depolarization -that is, in the ascending phase of the action potential -K V 11.1 opens rapidly, but K + flux is quickly terminated by channel inactivation. Following repolarization, release of inactivation is fast and is followed by slow deactivation. In this way, the channel is active during the depolarization of the action potential and during part of the diastolic phase of the cardiac cycle. In the later phase, the membrane potential is set at values at which the driving force for K + flux is low, but K + conductance buffers incoming depolarizations 202, 205 . Therefore, K V 11.1 has a pivotal role in setting the duration of the effective refractory period of the cardiac action potential. K V 11.1 mutations cause lQTS type 2 because deficient K V 11.1 function reduces repolarization and increases the possibility of torsades de pointes, ventricular fibrillation and sudden death 24, 206 . The considerable interest of the pharmaceutical industry in K V 11.1 is due to the involvement of this channel in drug-induced or acquired lQTS (alQT). K V 11.1 blockers such as dofetilide (compound Nature Reviews | Drug Discovery . drugs in this class are efficacious in preventing and reverting atrial fibrillation and flutter, but their intrinsic arrhythmogenic activity largely restricts their use (often to intensive-care settings). As discussed above, K V 11.1 can be blocked by many structurally diverse compounds, and regulatory agencies request that all new drug candidates are tested for this possibility.
The large number of compounds identified as channel modulators has made it possible to identify several K V 11.1 activators in recent years (FIG. 6 ), and one is a natural toxin (mallotoxin 213 ). owing to its complex kinetics, the activity of K V 11.1 can be increased by altering its activation, inactivation or deactivation. All of these properties are modified by the various K V 11.1 activators: NS1643 and NS3623 reduce inactivation, RPR260243 delays deactivation and Pd307243 and A935142 alter all three of these properties.
These activators have two potential therapeutic applications. First, they could be used to rescue alQT. Second, K V 11.1 activators could become a novel class of antiarrhythmics, as they have been reported to reduce electrical heterogeneity in the myocardium and thereby the possibility of re-entry 205 . Concerns about the feasibility of such an antiarrhythmic approach have been raised by a recently described cardiac condition, termed short QT syndrome 214 , in which a faster repolarization results in a shorter QT interval. However, experimental models suggest that shortening of the QT interval poses a low risk of arrhythmia 205 . of the 300 lQTS-inducing mutations in K V 11.1 that have been identified, a large proportion results in defective channel trafficking 215 . Interestingly, K V 11.1 blockers also increase the cell surface expression of the channel. However, there is no direct relationship between channel blocking efficiency and trafficking, as compounds that do not block the channels, such as thapsigargin or fexofenadine, also increase surface expression 216 . Compounds such as these could directly improve membrane targeting of the channel by acting as molecular chaperones. It is therefore conceivable to use modifiers of K V 11.1 trafficking to ameliorate lQTS that originates from surface expression defects of K V 11.1 (ReF. 217) .
Besides its relevance in cardiac physiology, overexpression of a primate-specific, brain isoform of K V 11.1 (encoded by KCNH2-3.1) -which lacks an N-terminal domain crucial for slow deactivation and therefore induces high-frequency, non-adaptive firing patterns in cultured cortical neurons -has recently been linked to an increased risk of schizophrenia 218 . It was suggested that isoform-specific K V 11.1 inhibitors might be useful for the treatment of schizophrenia. K V 11.1 has also been extensively characterized in tumours 219 . As discussed for K V 10.1, the expression of K V 11.1 seems to be required for tumour cell proliferation. Indeed, K V 11.1 blockers impair the proliferation of tumour cells. K V 11.1 also interacts with integrins to regulate survival and migration, and is implicated in the regulation of apoptosis [220] [221] [222] [223] [224] [225] [226] . Thus, available data suggest K V 11.1 as a target for cancer therapy, but the concomitant inhibition of I Kr would initially seem a considerable hurdle for such an approach. Several considerations should be made in this regard. The risk to benefit profile of an anticancer drug is radically different from that of compounds for the treatment of benign conditions. Additionally, there are at least three alternative transcripts of K V 11.1 (ReFs 227, 228) , which are differentially expressed in the heart and in tumour cells. This opens the possibility to selectively inhibit the channel in tumours while preserving heart function, in a similar way as discussed above for schizophrenia.
Finally, it has recently been shown that an anticancer compound (the cyclin-dependent kinase inhibitor roscovitine) that is in Phase II clinical trials 229 is an efficient blocker of K V 11.1 but does not induce arrhythmia, probably owing to its low affinity for the closed and inactivated states of the channel. However, K V 11.1 inhibition could not only directly contribute to the prevention of tumour progression but might also treat some collateral effects of neoplasia. For example, K V 11.1 expression is required for muscle wasting related to inactivity and neoplasia 230 , presumably through its role in the activation of ubiquitin-dependent protein degradation.
Outlook and challenges
Since the first cloning of a K V channel more than 20 years ago, remarkable progress has been made in our understanding of the diverse physiological and pathophysiological roles of this class of channels. However, owing to the difficulties of targeting ion channels in general, medicinal chemistry efforts in this area have considerably lagged behind drug development in the fields of G protein-coupled receptors and protein kinases. K V channel drug discovery faces the same general problems as all other target fields -particularly that transgenic approaches can be misleading for target evaluation. Although heterozygous K V 7.2 +/-mice and K V 7.2-transgenic mice in which channel expression was drastically reduced 231, 232 have been used to validate K V 7.2 as a target for anticonvulsive therapy, many other transgenic approaches have been disappointing. There are many possible reasons for this, ranging from developmental compensation to different physiological roles of particular K V channels in different species. Striking examples of such species-specific differences are the lack of importance of K V 1.3 in mouse T cell function (see the section on K V 1.3) or the different roles of K V 1.4, K V 1.5, K V 4.2 and K V 4.3 in the cardiac action potential of different species 233 . Another hurdle to K V channel drug discovery is the fact that traditional methods developed for highthroughput screening of ion channels, such as binding assays or voltage-sensitive fluorescent probes, measure ion channel activity indirectly and can therefore miss compounds that interact with a particular conformational (gating) state of the channel. Furthermore, these assays can be susceptible to potentially misleading actions of compounds with poor physiochemical properties (such as low solubility, 'sticky' hydrophobic compounds), which can result in incorrect 'hit' identification or can cause active compounds to be missed (see BOX 2 for an overview of screening technologies). However, with the recent advent of high-or at least medium-throughput electrophysiology, which measures K V channel function directly and is able to identify state-dependent modulators, this situation is currently changing. As a result, pharmaceutical companies and academic screening centres are becoming increasingly successful at identifying potent and selective K V channel modulators.
The discovery of K + channel-modulating drugs is also increasingly assisted by structural information. The X-ray structures of K + channels in the open and closed states have revolutionized our knowledge about how drugs target K + channels. Currently, a co-crystal of the bacterial KcsA channel with tetrabutyl ammonium is the only visualized example of a ligand bound in the inner pore of a K + channel. However, results of mutational, electrophysiological and ligand-binding experiments are increasingly interpreted in structural terms using homology modelling and ligand docking.
despite this impressive progress, true channel structure-based drug design is currently not possible for K V channel modulators. It is hoped that co-crystal structures will eventually be resolved for medically important channels, such as K V 1.5, K V 7.2 and K V 11.1, with drug molecules bound. It remains a challenge to decide which of the available structures to use for homology modelling, as the inner-pore geometry varies substantially between the KcsA, K V AP and K V 1.2 structures 9 . other crucial issues are the possible coexistence of several drug-binding modes and an incomplete understanding of the influence of protein dynamics on high-affinity drug binding. like all ion channels, K V channels are 'moving targets' that undergo large conformational changes, switching between open, closed and inactivated states on a millisecond timescale. These changes in gating state are often accompanied by substantial changes in the conformation of drug binding sites, resulting in a phenomenon referred to as statedependent inhibition. It is not yet possible to model the 'trapping' of the channel in one of its many possible conformations by a drug.
Based on the current status of the K V channel field, it is to be expected that drugs modulating the channels discussed in this article will reach the clinic within the next few years. Non-selective K V channel modulators such as fampridine may have already found a niche in the potential treatment of multiple sclerosis. The K V 7.2/K V 7.3 activator retigabine has completed Phase III clinical trials for the treatment of epilepsy and is currently the most advanced novel K V channel modulator. Next-generation modulators of K V 7.2/K V 7.3 channels are only a few years behind retigabine in their development. However, despite more than 20 years of work, a K V channel modulator specifically designed for a particular target has yet to reach the market. other K V channels, such as K V 2.1 or K V 3.4, may offer attractive therapeutic opportunities in the future, but need to be explored further before they can be regarded as valid drug targets. It will also be interesting to see whether there will be any repositioning of existing marketed drugs in the K V channel field. For example, could an 'old' drug such as clofazimine find new life as a K V 1.3 inhibitor-based immunosuppressant? Therefore, although the development of drugs that target K V channels is at an early stage and presents many challenges, there are considerable opportunities for future success.
Note added in proof Another interesting mode of interaction has recently been identified between K V 3.1 and the polycyclic cigutera toxin gambierol, which is produced by the dinoflagellate Gambierdiscus toxicus. This lipophilic ether toxin inserts into the space between S5 and S6 outside of the permeation pathway on the side of the helices facing the lipid and prevents the channel from opening by stabilizing the closed state 260 .
